RECRUITING

Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma

Description

The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)

Conditions

Liver Cancer
Talk to us

Related Conditions:

Liver Cancer

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)

Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma

Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma

Condition
Liver Cancer
Intervention / Treatment

-

Contacts and Locations

Stanford

Stanford University School of Medicine, Stanford, California, United States, 94305

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI.
  • * Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia.
  • * Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stanford University,

Samuel So, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

2025-12